降压药依普利酮的效果怎么样

The clinical treatment effect is relatively good. It is a selective aldosterone receptor antagonist. It is used in the clinical treatment of heart failure and hypertension. If it is to treat heart failure, it can improve the quality of life of patients. If it is to treat hypertension, it can be used alone or in combination with other antihypertensive drugs to treat hypertension. It has a relatively good clinical effect. There are also a very small number of patients who are not sensitive to the efficacy of the drug and have no therapeutic effect.

Subgroup analysis of the EPHESUS study showed that the effect of eplerenone on reducing overall mortality was more obvious in patients with hypertension. A comparative study on the efficacy and tolerability of 499 patients with grade 1 or 2 hypertension who were randomized to receive enalapril or eplerenone showed that at 6 months, enalapril was as effective as eplerenone (Inspra) in reducing systolic blood pressure (eplerenone decreased by 14.5 mmHg; enalapril decreased by 12.7 mmHg; P=0.199) and diastolic blood pressure (eplerenone decreased by 11.2 mmHg; enalapril decreased by 11.3 mm). Hg; P=0.910). After 12 months, the two groups were also similar (eplerenone -16.5/-13.3mmHg; enalapril -14.8/-14.1mmHg, P values ​​0.251 and 0.331 respectively).

About 2/3 of the patients in each group achieved normal blood pressure at 6 months with the above single treatment. In the eplerenone group, the reduction in blood pressure was independent of renin levels, unlike enalapril. Both groups could reduce proteinuria above normal levels, but the eplerenone group was more significant (-61.5% vs -25.7%; P=0.01).

It can be seen that (Inspra) not only has a significant effect on the treatment of hypertension, but also plays a very good role in reducing proteinuria, making it a good choice for patients with hypertension.